Table 1.
10 Drug-diagnostic combinations.
| Brand-Name (generic)/Indication | Test(s)/Biomarker(s) | Co-Developed | Medicare Part B or Part D |
|---|---|---|---|
| Herceptin (trastuzumab)—breast cancer | HER-2/neu receptor | Yes | Part B |
| Gleevec (imatinib)—chronic myeloid leukemia | Philadelphia chromosome/BCR-ABL | No | Part D |
| Erbitux (cetuximab)—colorectal cancer | EGFR expression/K-RAS mutation | No | Part B |
| Tarceva (erlotinib)—non-small cell lung cancer | Cobas EGFR mutation | No | Part D |
| Sprycel (dasatinib)—chronic myeloid leukemia | Philadelphia chromosome/BCR-ABL | No | Part D |
| Vectibix (panitumumab)—colorectal cancer | EGFR expression/K-RAS mutation | No | Part B |
| Tykerb (lapatinib)—breast cancer | HER-2/neu receptor | No | Part D |
| Selzentry (maraviroc)—HIV | CCR5 receptor | No | Part D |
| Zelboraf (vemurafenib)—non-small cell lung cancer | Cobas BRAF V600E | Yes | Part D |
| Xalkori (crizotinib)—melanoma | ALK | Yes | Part D |
We examine reimbursement of 10 drug-diagnostic combinations. Three of the drug-diagnostic combinations were co-developed while seven were post-hoc. Three are physician-administered (Medicare Part B), and seven self-administered (Medicare Part D).